Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1-2, multicenter, open-label study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 given in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

Next Previous
X
Search
Trial Profile

A phase 1-2, multicenter, open-label study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 given in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AEG 35156 (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aegera Therapeutics

    • Most Recent Events

    • 31 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned end date changed from 1 Jan 2009 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 08 Jan 2009 First patient has been dosed. Recruitment for this trial is expected to be completed prior to the end of 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top